NCT05407155

Bevacizumab Plus Nab-paclitaxel and Platinum for Immunotherapy-treated Non-squamous Non-small Cell Lung Cancer

BEvacizumab Plus Nab-pacliTaxel and plaTinum as sEcond-line theRapy for Driver-gene-negative Non-squamous Non-small Cell Lung Cancer Progressed After First-line Immune Checkpoint Inhibitor-based Regimen

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 56 (estimated)
• Sponsor: Fudan University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Immune checkpoint inhibitor (ICI)-based regimen has been widely used in first-line treatment of driver-gene-negative non-squamous non-small cell lung cancer. This study investigate the efficacy and safety of the combination of bevacizumab plus nab-paclitaxel and platinum as second-line treatment for driver-gene-negative non-squamous non-small cell lung cancer patients progressed after ICI-based treatments.

Conditions

• Non-small Cell Lung Cancer Metastatic

Interventions

Type	Name	Description
COMBINATION_PRODUCT	bevacizumab plus nab-paclitaxel and platinum	Bevacizumab is given as 15mg/kg every 3 weeks. Nab-paclitaxel is given as 260 mg/m2 every 3 weeks for 4 cycles at most. Platinum includes caboplatin or cisplatin, which is chosed by phycisians. Carboplatin was calculated using AUC equals 5 for 4 cycles at most, and cisplatin was given as 75mg/m2 for 4 cycles at most. Bevacizumab is given untill disease progression or intolerated toxicities.

Timeline

• Start date: 2022-06-01
• Primary completion: 2023-06-01
• Completion: 2024-06-01
• First posted: 2022-06-07
• Last updated: 2022-06-07